{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:03:58Z","timestamp":1761919438917},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms are heterogeneous disorders. JAK2 mutation testing and karyotyping are routinely used for diagnosis but have not been incorporated into risk stratification in Philadelphia chromosome\u2013negative myeloproliferative neoplasms. This study correlated cytogenetic abnormalities with disease stage and JAK2 status. A total of 179 cases were analyzed for the JAK2 mutation. Among them, cytogenetic data were available for 97 cases\u201445 of 106 JAK2+ and 52 of 73 JAK2\u2013. The JAK2+ group showed a higher frequency of cytogenetic anomalies than the JAK2\u2013 group (23\/45 [51%] vs 14\/52 [27%]). Chromosome 9, chromosome 7, and 20q\u2013 were recurrent abnormalities in the JAK2+ group, whereas 13q\u2013 and trisomy 21 were common in the JAK2\u2013 group. In the JAK2+ group, chromosome 7 and complex cytogenetic abnormalities were associated with excess blasts\/blastic transformation (P &amp;lt; .05), whereas no cases with 20q\u2013 underwent blastic transformation. Our results suggest that incorporation of JAK2 mutation testing and karyotyping allows for monitoring of disease progression with prognostic and therapeutic implications.<\/jats:p>","DOI":"10.1309\/ajcps6c8evycqnrm","type":"journal-article","created":{"date-parts":[[2011,4,18]],"date-time":"2011-04-18T19:39:25Z","timestamp":1303155565000},"page":"709-719","source":"Crossref","is-referenced-by-count":15,"title":["Association of <i>JAK2<\/i> Mutation Status and Cytogenetic Abnormalities in Myeloproliferative Neoplasms and Myelodysplastic\/Myeloproliferative Neoplasms"],"prefix":"10.1093","volume":"135","author":[{"given":"Jennifer","family":"Dunlap","sequence":"first","affiliation":[{"name":"1Department of Pathology, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Kelemen","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicky","family":"Leeborg","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Braziel","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Olson","sequence":"additional","affiliation":[{"name":"2Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Press","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Huang","sequence":"additional","affiliation":[{"name":"3Department of Clinical Pathology, William Beaumont Hospital, Royal Oak, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Gatter","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Loriaux","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Fan","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,5,1]]},"reference":[{"key":"2023011911094049700_b1-1350709","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008","edition":"4th ed"},{"key":"2023011911094049700_b2-1350709","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"2023011911094049700_b3-1350709","doi-asserted-by":"crossref","first-page":"947","DOI":"10.4065\/80.7.947","article-title":"The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clinic Proc"},{"key":"2023011911094049700_b4-1350709","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"2023011911094049700_b5-1350709","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2023011911094049700_b6-1350709","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"2023011911094049700_b7-1350709","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutation of JAK2 exon 12 in patients with JAK2 (V618F)\u2013negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"2023011911094049700_b8-1350709","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00277-009-0745-3","article-title":"Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS\/MPN category [published online ahead of print May 5, 2009]","volume":"88","author":"Bacher","year":"2009","journal-title":"Ann Hematol"},{"key":"2023011911094049700_b9-1350709","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/sj.leu.2403989","article-title":"The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients [letter]","volume":"19","author":"Ohyashiki","year":"2005","journal-title":"Leukemia"},{"key":"2023011911094049700_b10-1350709","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2008-09-178541","article-title":"The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"2023011911094049700_b11-1350709","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International Prognostic Scoring System\u2013independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"key":"2023011911094049700_b12-1350709","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/cncr.21358","article-title":"Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia","volume":"104","author":"Tefferi","year":"2005","journal-title":"Cancer"},{"key":"2023011911094049700_b13-1350709","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"key":"2023011911094049700_b14-1350709","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"2023011911094049700_b15-1350709","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00277-004-0977-1","article-title":"Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information","volume":"84","author":"Bacher","year":"2005","journal-title":"Ann Hematol"},{"key":"2023011911094049700_b16-1350709","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0609.2009.01246.x","article-title":"Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance","volume":"83","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"key":"2023011911094049700_b17-1350709","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1600-0609.2007.01003.x","article-title":"Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates","volume":"80","author":"Gangat","year":"2008","journal-title":"Eur J Haematol"},{"key":"2023011911094049700_b18-1350709","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/(SICI)1098-2264(199906)25:2<134::AID-GCC9>3.0.CO;2-Y","article-title":"Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-related differences: a Children\u2019s Cancer Group study","volume":"25","author":"Bussey","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"2023011911094049700_b19-1350709","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.leu.2404104","article-title":"A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma [letter]","volume":"20","author":"Adelaide","year":"2006","journal-title":"Leukemia"},{"key":"2023011911094049700_b20-1350709","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.humpath.2005.12.002","article-title":"Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation [letter]","volume":"37","author":"Bousquet","year":"2006","journal-title":"Hum Pathol"},{"key":"2023011911094049700_b21-1350709","first-page":"500","article-title":"Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation [reply]","volume":"37","author":"Tsankov","year":"2006","journal-title":"Pathol"},{"key":"2023011911094049700_b22-1350709","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"2023011911094049700_b23-1350709","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"2023011911094049700_b24-1350709","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"2023011911094049700_b25-1350709","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"2023011911094049700_b26-1350709","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"2023011911094049700_b27-1350709","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","article-title":"JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival","volume":"24","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"2023011911094049700_b28-1350709","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F JAK2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"key":"2023011911094049700_b29-1350709","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"key":"2023011911094049700_b30-1350709","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"2023011911094049700_b31-1350709","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3324\/haematol.13721","article-title":"JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post\u2013polycythemia vera and post\u2013essential thrombocythemia myelofibrosis","volume":"94","author":"Guglielmelli","year":"2009","journal-title":"Haematologica"},{"key":"2023011911094049700_b32-1350709","first-page":"144","article-title":"Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies","volume":"23","author":"Ellis","year":"1986","journal-title":"Semin Hematol"},{"key":"2023011911094049700_b33-1350709","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/1097-0142(19850201)55:3<582::AID-CNCR2820550318>3.0.CO;2-O","article-title":"The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis","volume":"55","author":"Miller","year":"1985","journal-title":"Cancer"},{"key":"2023011911094049700_b34-1350709","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"2023011911094049700_b35-1350709","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/cncr.21297","article-title":"Leukemic transformation of polycythemia vera","volume":"104","author":"Passamonti","year":"2005","journal-title":"Cancer"},{"key":"2023011911094049700_b36-1350709","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.leukres.2008.09.009","article-title":"Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis","volume":"33","author":"Tefferi","year":"2009","journal-title":"Leuk Res"},{"key":"2023011911094049700_b37-1350709","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"key":"2023011911094049700_b38-1350709","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2353\/jmoldx.2008.070061","article-title":"Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a clonal hematological non\u2013mast cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F","volume":"10","author":"Sotlar","year":"2008","journal-title":"J Mol Diagn"},{"key":"2023011911094049700_b39-1350709","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2010-02-270330","article-title":"Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience","volume":"116","author":"Medeiros","year":"2010","journal-title":"Blood"},{"key":"2023011911094049700_b40-1350709","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype","volume":"26","author":"Breems","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023011911094049700_b41-1350709","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1182\/blood-2004-11-4319","article-title":"Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia [letter]","volume":"105","author":"Strasser-Weippl","year":"2005","journal-title":"Blood"},{"key":"2023011911094049700_b42-1350709","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1002\/cncr.22318","article-title":"Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia","volume":"107","author":"Strasser-Weippl","year":"2006","journal-title":"Cancer"},{"key":"2023011911094049700_b43-1350709","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2007.02.009","article-title":"Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications","volume":"255","author":"Panani","year":"2007","journal-title":"Cancer Lett"},{"key":"2023011911094049700_b44-1350709","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","article-title":"Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders","volume":"108","author":"Kralovics","year":"2006","journal-title":"Blood"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/135\/5\/709\/48771125\/ajcp_135_5_709.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/135\/5\/709\/48771125\/ajcp_135_5_709.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T11:51:58Z","timestamp":1674129118000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/135\/5\/709\/1766057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,1]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,5,1]]},"published-print":{"date-parts":[[2011,5,1]]}},"URL":"https:\/\/doi.org\/10.1309\/ajcps6c8evycqnrm","relation":{},"ISSN":["1943-7722","0002-9173"],"issn-type":[{"value":"1943-7722","type":"electronic"},{"value":"0002-9173","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,5,1]]},"published":{"date-parts":[[2011,5,1]]}}}